These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 25260377)
41. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386 [TBL] [Abstract][Full Text] [Related]
42. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090 [TBL] [Abstract][Full Text] [Related]
43. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858 [TBL] [Abstract][Full Text] [Related]
44. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Sveistrup J; af Rosenschöld PM; Deasy JO; Oh JH; Pommer T; Petersen PM; Engelholm SA Radiat Oncol; 2014 Feb; 9():44. PubMed ID: 24495815 [TBL] [Abstract][Full Text] [Related]
45. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170 [TBL] [Abstract][Full Text] [Related]
46. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. Nakamura K; Ikeda I; Inokuchi H; Takayama K; Inoue T; Kamba T; Ogawa O; Hiraoka M; Mizowaki T J Radiat Res; 2018 Sep; 59(5):656-663. PubMed ID: 30085048 [TBL] [Abstract][Full Text] [Related]
47. Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy. Geier M; Astner ST; Duma MN; Jacob V; Nieder C; Putzhammer J; Winkler C; Molls M; Geinitz H Strahlenther Onkol; 2012 May; 188(5):410-6. PubMed ID: 22367410 [TBL] [Abstract][Full Text] [Related]
48. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581 [TBL] [Abstract][Full Text] [Related]
49. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity. Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181 [TBL] [Abstract][Full Text] [Related]
50. Image guided dose escalated prostate radiotherapy: still room to improve. Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007 [TBL] [Abstract][Full Text] [Related]
51. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Alongi F; Fogliata A; Navarria P; Tozzi A; Mancosu P; Lobefalo F; Reggiori G; Clivio A; Cozzi L; Scorsetti M Strahlenther Onkol; 2012 Nov; 188(11):990-6. PubMed ID: 23053143 [TBL] [Abstract][Full Text] [Related]
52. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135 [TBL] [Abstract][Full Text] [Related]
53. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy. Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662 [TBL] [Abstract][Full Text] [Related]
54. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy. Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H Anticancer Res; 2017 Oct; 37(10):5829-5835. PubMed ID: 28982908 [TBL] [Abstract][Full Text] [Related]
55. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Guerrero Urbano T; Khoo V; Staffurth J; Norman A; Buffa F; Jackson A; Adams E; Hansen V; Clark C; Miles E; McNair H; Nutting C; Parker C; Eeles R; Huddart R; Horwich A; Dearnaley DP Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):236-44. PubMed ID: 20171852 [TBL] [Abstract][Full Text] [Related]
56. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience. Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975 [TBL] [Abstract][Full Text] [Related]
57. Target localization and toxicity in dose-escalated prostate radiotherapy with image-guided approach using daily planar kilovoltage imaging. Nath SK; Sandhu AP; Sethi RA; Jensen LG; Rosario MD; Kane CJ; Parsons JK; Millard FE; Jiang SB; Rice RK; Pawlicki T; Mundt AJ Technol Cancer Res Treat; 2011 Feb; 10(1):31-7. PubMed ID: 21214286 [TBL] [Abstract][Full Text] [Related]
58. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889 [TBL] [Abstract][Full Text] [Related]
59. Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function. Girelli G; Franco P; Sciacero P; Cante D; Borca VC; Pasquino M; Annoscia S; Tofani S; La Porta MR; Ricardi U Anticancer Res; 2015 Jul; 35(7):4177-82. PubMed ID: 26124375 [TBL] [Abstract][Full Text] [Related]
60. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]